Overall, model-based treatment recommendations of E2F1-driven tumor diseases such as advanced bladder or breast cancer, have the potential to support cohort-specific treatment of patients to avoid therapy resistance and cope with aggressive cancers. Here, E2F1 is linked to breast carcinoma.